GlassScriptPhysician profile
Ammar Wahood
NPI 1720375611
$12,270.81
in general payments reported to CMS, 2019-2025
37 companies · $1,896 in 2025
The $1,896 reported for 2025 was more than what 78% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,876 · 2020: $2,278 · 2021: $2,260 · 2022: $1,168 · 2023: $1,316 · 2024: $1,475 · 2025: $1,896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,580 · Travel and Lodging: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,580.23 |
| Travel and Lodging | $107.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $3,617.73 | 2019-2024 | Senza |
| Boston Scientific Corporation | $2,648.28 | 2020-2025 | Wavewriter Alpha Prime 16, Intracept, Superion Indirect Decompression System |
| Abbott Laboratories | $2,543.88 | 2019-2025 | Proclaim, Eterna |
| Globus Medical, INC. | $610.70 | 2025 | Vyrsa V1, Senza |
| Merck Sharp & Dohme LLC | $291.13 | 2019-2023 | Bridion |
| Abbvie INC. | $275.34 | 2024-2025 | |
| Amgen INC. | $214.57 | 2019 | |
| Collegium Pharmaceutical, INC. | $199.34 | 2023-2025 | Xtampza, Belbuca |
| Pfizer INC. | $153.23 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $141.18 | 2024 | Voquezna |
| Spr Therapeutics, INC | $140.32 | 2025 | Sprint Pns System |
| Incyte Corporation | $124.92 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $123.68 | 2019 | |
| Qol Medical, LLC | $121.55 | 2020 | |
| Vertos Medical, INC. | $96.95 | 2019 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ammar Wahood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.